Multiples aspects of HIV resistance to antiretroviral drugs;Les multiples aspects de la résistance du VIH aux antirétroviraux

Medecine et Maladies Infectieuses

Volumn 30, Issue 9, 2000, Pages 551-564

  Clevenbergh, P ^a   Durant, J ^a   Garraffo, R ^b   Chaillou, S ^a   Cua, E ^c   Dellamonica, P ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b PASTEUR HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Antiretroviral drugs kinetics; Antiretroviral drugs resistance

Indexed keywords

ABACAVIR; ADEFOVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; NELFINAVIR; RITONAVIR; SAQUINAVIR;

HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; REVIEW; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

EID: 0033788116     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-077X(00)80022-0     Document Type: Review

References (123)

1. Antiretroviral drug resistance testing in HIV infection of adults: Implications for clinical management
2. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
3. Intracellular studies of the nucleoside reverse transcriptase inhibitor active metabolites: A review
4. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
5. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team
6. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
7. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-Infected patients
8. Virological response to protease inhibitor therapy in an HIV clinic cohort
9. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor
10. Predictors of long-term response to protease inhibitor therapy in a cohport of HIV-infected patients
11. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
12. Incidence and predictors of virologic failure of antiretroviral triple drug therapy in a community based cohort
13. Risk factors for virologic failure in a cohort of HIV patients receiving highly active antiretroviral therapy (HAART)
14. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
15. Hidden dangers of incompletely suppressive antiretroviral therapy
16. Int Antiviral News
17. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance
18. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
19. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study
20. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
21. Baseline resistance profile predicts response to ritonavir/saquinavir therapy in a community setting
22. Genotypic and phenotypic correlates of response to abacavir (ABC, 1592)
23. Drug resistance and short term virological response in patients prescribed multidrug rescue therapy
24. Relationship of phenotypic and genotypic resistance profiles to virological outcome in a trial of abacavir, nelfinavir, efavirenz and adefovir dipivoxil in patients with virological failure receiving indinavir (ACTG 372)
25. Virological response to nelfinavir, efavirenz, or both in patients with > 4 years of previous nucleoside RT inhibitors in ACTG 364
26. Viral load response to the addition of lamivudine correlates with phenotypic susceptibility to lamivudine and the presence of T215Y in the absence of M184V
27. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
28. Relationship between phenotype and viral response in heavily pretreated patients with nucleoside analogue reverse transcriptase inhibitor - And protease inhibitor - Containing regimens
29. Responses to salvage therapy with an efavirenz and adefovir-based regimen in antiretroviral experienced patients: A genotypic study
30. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
31. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase
32. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
33. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance
34. Multidrug resistance genotypes (insertions in the beta3-beta4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: Incidence and association with other resistance mutations
35. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease
36. Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study
37. Treatment of human immunodeficiency virus type 1 in fected cells with combinations of HIV-1 specific inhibitors results in a different resistance pattern than does treatment with a single-drug therapy
38. Drug concentration heterogeneity facilitates the evolution of drug resistance
39. Interactions of antiretroviral drugs
40. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents
41. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity
42. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients
43. Plasma concentrations of saquinavir determine HIV-1 RNA response over a 48-week period
44. Plasma levels of indinavir (IDV) and virological treatment failure in HIV-infected patients
45. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study
46. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study
47. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
48. Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study
49. The relationship between ritonavir plasma levels and side-effects: Implications for therapeutic drug monitoring
50. The limited value of therapeutic drug monitoring in HIV infection
51. The promise of therapeutic drug monitoring in HIV infection
52. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic guided therapy: Pharmacological data from the Viradapt study
53. Factors influencing the emergence of resistance to indinavir: Role of virologic, immunologic, and pharmacologic variables
54. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy
55. Saquinavir, an HIV protease inhibitor, is transported by P-glyco-protein
56. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: Implications for transmission
57. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples
58. Clinical implications of HIV dynamics and drug resistance in macrophages
59. Multiple drug resistance mutations in human immunodeficiency virus in semen but not blood of a man on antiretroviral therapy
60. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
61. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
62. Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load
63. Viral dynamics of HIV: Implications for drug development and therapeutic strategies
64. Suppression of plasma viral load below 20 copies/mL is required to achieve a long-term response to therapy
65. Managing resistance to anti-HIV drugs
66. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
67. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group
68. Brief report: Primary infection with zidovudine-resistant human immunodeficiency virus type 1
69. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance
70. Reduced antiviral drug susceptibility among patients with primary HIV infection
71. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
72. HIV-1 drug resistance in newly infected individuals
73. Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drugs users
74. Prevalence of resistance mutations inantiviral naive patients: French national study
75. Transmission of antiretroviral-drug-resistant HIV-1 variants
76. RNA virus fitness
77. Lethal mutagenesis of HIV with mutagenic nucleoside analogs
78. The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase
79. Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1
80. Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential
81. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
82. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity
83. Spanish consensus conference on drug resistance testing in clinical practice. HIV drug resistance Spanish panel
84. Four drug-HAART in primary HIV-1 infection: Clinical benefits and virologic parameters
85. Zidovudine associated resistance mutations can be selected in patients receiving long-term exposure to stavudine
86. Plum interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype
87. Antiretroviral therapy in adults: Updated recommandations of the International AIDS Society-USA Panel
88. 1998 Revision to the British HIV Association guidelines for antiretroviral treatment of HIV sero-positive individuals. BHIVA Guidelines Writing Committee
89. The case for more cautious, patient-focused antiretroviral therapy